Business Context and Reporting Period
This Form 8-K Current Report was filed by AmerisourceBergen Corporation (now Cencora, Inc.) on May 19, 2020. The filing documents the completion of a debt offering and the entry into a material definitive agreement regarding the issuance of senior notes.
Key Financial Metrics and Transaction Details
The Company completed the sale of $500,000,000 aggregate principal amount of 2.800% Senior Notes due May 15, 2030. The filing does not provide specific revenue, profit, cash flow, or margin data for the period, as this is a transactional report rather than a periodic financial statement.
- Principal Amount: $500,000,000
- Interest Rate: 2.800% per year
- Maturity Date: May 15, 2030
- Interest Payment Dates: Semiannually on May 15 and November 15, beginning November 15, 2020
- Security Status: Unsecured and unsubordinated obligations of the Company; structurally subordinated to subsidiary indebtedness.
Material Changes and Covenants
The issuance of the Notes represents a new direct financial obligation. The Indenture imposes specific limitations on the Company and its restricted subsidiaries, including:
- Limits on creating liens and entering into sale and leaseback transactions.
- Restrictions on mergers, consolidations, or the sale of substantially all assets.
- Redemption Terms: The Company may redeem the Notes prior to February 15, 2030 at a "make-whole" price. On or after February 15, 2030, they may be redeemed at 100% of the principal amount plus accrued interest.
- Change of Control: In the event of a change of control, the Company must offer to purchase the Notes at 101% of the principal amount plus accrued interest.
Outlook, Risks, and Contingencies
The filing includes a comprehensive cautionary note regarding forward-looking statements and identifies significant risks that could materially affect future performance:
- Regulatory and Legal: Risks related to opioid litigation, government enforcement regarding controlled substances, and compliance with the Corporate Integrity Agreement.
- Market and Pricing: Unfavorable trends in pharmaceutical pricing, competition, and declining reimbursement rates.
- COVID-19 Impact: Potential disruption to operations, changes in customer/supplier payment terms, and risks of supplier or customer insolvency due to the pandemic.
- Strategic Relationships: Risks associated with the long-term relationship with Walgreens Boots Alliance, Inc.
- Financial Risks: Interest rate fluctuations, foreign currency exchange rate risks, and potential impairment of goodwill.
Investor Verification Checklist
- Verify the full text of the Ninth Supplemental Indenture (Exhibit 4.1) for specific covenant definitions and exceptions.
- Review the news release (Exhibit 99.1) for details on the use of proceeds from the $500 million offering.
- Monitor the status of pending opioid litigation and related legal proceedings referenced in the risk factors.
- Assess the impact of COVID-19 on the Company's major customers and suppliers as disclosed in the risk section.
- Confirm the Company's ability to meet semiannual interest payments starting November 15, 2020.